A Study of Lipid Metabolism and Mitochondrial Function in Myeloid Cells and Total Aortic Tissue in Patients With Ascending Thoracic Aortic Aneurysm (ATA) and Bicuspid (BA) or Tricuspid (TA) Aortic Valves.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Additional blood samples, Collection of discarded ascending aortic tissue.
- Who it may be relevant to
- Registry conditions: Ascending Aortic Aneurysm. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Prospective, Single-center, Open-label Study of Lipid Metabolism and Mitochondrial Function in Myeloid Cells and Total Aortic Tissue in Patients With Ascending Thoracic Aortic Aneurysm (ATA) and Bicuspid (BA) or Tricuspid (TA) Aortic Valves.
Overview
Ascending aortic aneurysms (AAAs) are serious conditions that can lead to aortic dissections or ruptures, carrying a high risk of mortality. Their pathophysiology is based on complex mechanisms involving inflammatory and metabolic processes, as well as alterations in mitochondrial function. The presence of a bicuspid aortic valve (BAV) or tricuspid aortic valve (TAV) significantly influences the progression and severity of aneurysms. Bicuspid aortic valve (BAV) patients often develop aortic aneurysms earlier, as early as age 40-50, whereas tricuspid aortic valve (TAV) patients generally present with a degenerative condition that appears later (after age 50). The objective of this study is to compare the inflammatory, metabolic, and transcriptomic signatures of myeloid cells and total aortic tissue between BAV and TAV patients. These analyses will help identify specific molecular mechanisms, potential biomarkers, and therapeutic targets. To ensure pathophysiological homogeneity, patients with aneurysms of genetic origin (Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, etc.) will be excluded.
Interventions
- Procedure Additional blood samples
Additional blood sample are collected at the time of routine clinical blood sampling for recherche analyses. - Procedure Collection of discarded ascending aortic tissue
The aneurysmal portion of the ascending aorta (surgical specimen), which would otherwise be discarded, is collected for research purposes. No other tissue is collected, and the research protocol does not alter the surgical procedure.
Primary outcome measures
- Inflammatory, metabolic, and transcriptomic markers of myeloid cells and aortic tissue [Time frame: At the time of surgery]
Eligibility criteria
Inclusion criteria
- Individuals who have given their consent
- Patients with an ascending aortic aneurysm for which surgical replacement is indicated
- Age > 18 years
- Scheduled surgery
- Preoperative ultrasound confirmation of the heart valve architecture (bicuspid or tricuspid valve)
Exclusion criteria
- A person subject to a legal protective measure (guardianship, conservatorship)
- A person subject to a judicial safeguard measure - A pregnant woman, a woman in labor, or a breastfeeding woman
- Adults who are legally incapacitated or unable to give consent
- Emergency surgical procedures
- Patients with uncontrolled inflammatory or autoimmune conditions
- Patients with a history of recent acute infection (within the last 3 months or still undergoing treatment)
- Patients with a condition requiring immunosuppressants - Patients with a confirmed or suspected genetic aneurysm (Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, etc.)
- Patients with a history of cardiac surgery
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- Chu Dijon Bourgogne — Dijon
Identifiers
NCT: NCT07695545 · BLITTI 2026-1